clinical trial · NCT07947134
A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours
Solid TumoursGSK5864399
brief summary
This study will evaluate a new drug, GSK5864399, in adult participants with advanced solid tumours. The study will assess how well the drug works against cancer, how safe it is, how the body processes the drug, and its effect on the tumours.
started
Nov 25, 2026
primary completion
Nov 16, 2029
completion
Dec 28, 2029
last updated
Nov 18, 2026
official title
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of GSK5864399 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Selected Advanced Solid Tumours
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol